Pharma & Biotech: Hiring, Funding And Leadership Signals
Every update we hold from an employer we have filed under Pharma & Biotech: 944 updates from 98 sources, across 795 employers. Each one links to the filing or report that makes the claim. These are counts of documents we have read, so they measure what we have found and can cite, not everything that happened. They also include the routine officer filings the tracker sets aside by default, so its figure for this place is lower than the one above.
Covering 1 Jan 2026 to 4 Sep 2026
$7,176,372,751 disclosed across 315 funding updates. Totals cover the 292 of 315 funding updates that are money the employer raised, stated in US dollars. We leave out amounts in other currencies rather than convert them at a rate nobody published. We also leave out money that moved for another reason: a sale price, a fund close, a company spending rather than raising, government funding, a pledge.
Employers We Hold The Most On
Ranked by how many updates we hold, then by how many independent sources are behind them. That is a measure of our own coverage rather than of an employer's size. Each name links to everything we hold for that employer.
- Cingulate Inc. 5 updates
- Immunic, Inc. 4 updates
- Standard BioTools Inc. 4 updates
- Sanofi 3 updates
- GSK plc 3 updates
- Zenas BioPharma, Inc. 3 updates
- Alkermes plc 3 updates
- NEONC TECHNOLOGIES HOLDINGS, INC. 3 updates
What The Updates Are About
Countries In This Industry
A name with a page of its own links to it. One we do not hold enough on for a page of its own links to the tracker filtered to it, which shows every update behind the count.
- United States 763 updates
- United Kingdom 25 updates
- Canada 17 updates
- Israel 16 updates
- France 9 updates
- India 9 updates
- Ireland 7 updates
- South Korea 6 updates
Recent Updates
The 12 most recent, in the order the tracker itself uses. Every line links to the document it came from. See all 944 updates for Pharma & Biotech.
- 2026-09-04Headcount Not Stated Leadership moves
HARROW, INC. 8-K filing (Item 5.02): officer or director change
Harrow's Chief Accounting Officer departs; the CFO adds the accounting-officer role with no extra pay.
- 2026-09-02Adding Roles Ways of working
Yicheng Plans China Training for 100 Cameroonians Ahead of Pharma Plant Launch
Yicheng Pharmaceutical Group will train 100 Cameroonians in China for roles in its new Yaounde complex, with plans to add 1,500 jobs in pharma and biotech manufacturing and clinical healthcare.
- 2026-08-24Adding Roles Ways of working
Bayer anuncia 215 nuevos puestos en su Centro de Servicios Compartidos
Bayer is hiring 215 new roles at its Shared Services Center in Chile, direct headcount growth for the pharma and biotech company's operations there.
- 2026-08-21Headcount Not Stated Ways of working
Genentech invests $750M in new factory
Genentech opens a new drug delivery device facility in Hillsboro, OR, with a $750M investment. The announcement does not disclose hiring plans.
- 2026-08-19Headcount Not Stated Growing and expanding
KaliVir Immunotherapeutics Announces Closing of $14 Million Series A Extension Financing
KaliVir Immunotherapeutics has $14M of new capital in a Series A extension. The announcement does not disclose hiring plans; watch its careers page for pharma and biotech roles.
- 2026-08-18Headcount Not Stated Growing and expanding
Amylyx Pharma lance une levée de fonds de 350 millions de dollars pour financer son médicament pour la glycémi
Amylyx Pharma has $350M of new capital for its glycemia medication. The announcement does not disclose hiring plans; watch its careers page for pharma and biotech roles.
- 2026-08-14Adding Roles Growing and expanding
Replimune rehires commercial team, secures $150M after FDA reversal on melanoma drug
Replimune is hiring a commercial lead in the United States to launch its melanoma drug Tudriqev, following $150M in funding and FDA approval.
- 2026-08-14Headcount Not Stated Leadership moves
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
BeyondSpring's leadership transition aligns the organization around focused advancement of the DUBLIN-4 program in NSCLC post-ICI.
- 2026-08-13Headcount Not Stated Leadership moves
Zenas BioPharmas Nettoverlust im 2. Quartal weitet sich aus; CFO tritt zurück
Zenas BioPharma, a pharma and biotech company, reports a wider Q2 net loss alongside the resignation of its CFO, leaving the finance leadership seat open. The announcement names no hiring plans for the role or elsewhere.
- 2026-08-13Headcount Not Stated Growing and expanding
Khartis Therapeutics Raises $50M To Advance Oral Immunology Drugs
Khartis Therapeutics raised $50M in Series B for oral immunology drugs. The announcement does not disclose hiring plans; watch its careers page for pharma and biotech roles.
- 2026-08-12Headcount Not Stated Growing and expanding
Boulevard starts up with $65M to pursue targeted autoimmune drugs
Boulevard has $65M of new capital for autoimmune drug development. The announcement does not disclose hiring plans; watch its careers page for pharma and biotech roles.
- 2026-08-11Headcount Not Stated Leadership moves
Bicara Therapeutics Announces Strategic Leadership Transitions
Bicara Therapeutics transitions executive leadership in Boston, with Ryan Cohlhepp becoming CEO and Claire Mazumdar moving to Vice Chair of the Board, effective January 2027.
Pharma & Biotech: Hiring, Funding And Leadership Signals. Talent Intelligence Tracker, AskTheRecruiter.com. Accessed Sep 5, 2026. https://asktherecruiter.com/blog/talent-intelligence-tracker/industry/pharma-and-biotech/ Licensed CC BY 4.0; every record links to the document behind it.The read-through on each line is our interpretation. The headline and figures come from the linked source. Data licensed CC BY 4.0. Every country, city and industry we cover · Every source · Back to the tracker